Robert E. O’Neill

814 total citations
14 papers, 636 citations indexed

About

Robert E. O’Neill is a scholar working on Epidemiology, Microbiology and Molecular Biology. According to data from OpenAlex, Robert E. O’Neill has authored 14 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 8 papers in Microbiology and 3 papers in Molecular Biology. Recurrent topics in Robert E. O’Neill's work include Pneumonia and Respiratory Infections (8 papers), Bacterial Infections and Vaccines (8 papers) and Influenza Virus Research Studies (7 papers). Robert E. O’Neill is often cited by papers focused on Pneumonia and Respiratory Infections (8 papers), Bacterial Infections and Vaccines (8 papers) and Influenza Virus Research Studies (7 papers). Robert E. O’Neill collaborates with scholars based in United States, United Kingdom and Finland. Robert E. O’Neill's co-authors include Peter Palese, Thorsten Wolff, Mirella Salvatore, Adolfo Garcı́a-Sastre, Thomas Muster, Hongyong Zheng, John L. Perez, Thomas R. Jones, Kathrin U. Jansen and Laura J. York and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Virology and Virology.

In The Last Decade

Robert E. O’Neill

14 papers receiving 609 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert E. O’Neill United States 12 514 214 187 143 106 14 636
Laura Couzens United States 15 722 1.4× 191 0.9× 39 0.2× 170 1.2× 147 1.4× 19 831
Sandrine Tilman Italy 10 440 0.9× 136 0.6× 287 1.5× 107 0.7× 85 0.8× 12 567
Devra Huey United States 12 215 0.4× 103 0.5× 33 0.2× 319 2.2× 88 0.8× 18 583
Teddy John Wohlbold United States 14 1.0k 2.0× 433 2.0× 25 0.1× 272 1.9× 192 1.8× 19 1.2k
Taff Jones Canada 11 260 0.5× 152 0.7× 35 0.2× 155 1.1× 60 0.6× 20 396
Sylviane Poncelet Belgium 12 544 1.1× 192 0.9× 45 0.2× 49 0.3× 56 0.5× 19 655
Kathryn Edenborough Australia 10 209 0.4× 159 0.7× 31 0.2× 111 0.8× 51 0.5× 18 395
Jacqueline de Vries‐Idema Netherlands 13 196 0.4× 171 0.8× 22 0.1× 105 0.7× 89 0.8× 22 355
Chiara Gentile Italy 12 403 0.8× 231 1.1× 13 0.1× 197 1.4× 138 1.3× 17 635
Sonja Kothlow Germany 12 179 0.3× 234 1.1× 62 0.3× 69 0.5× 79 0.7× 18 403

Countries citing papers authored by Robert E. O’Neill

Since Specialization
Citations

This map shows the geographic impact of Robert E. O’Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. O’Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. O’Neill more than expected).

Fields of papers citing papers by Robert E. O’Neill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. O’Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. O’Neill. The network helps show where Robert E. O’Neill may publish in the future.

Co-authorship network of co-authors of Robert E. O’Neill

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. O’Neill. A scholar is included among the top collaborators of Robert E. O’Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. O’Neill. Robert E. O’Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Beeslaar, Johannes, Judith Absalon, Annaliesa S. Anderson, et al.. (2020). MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infectious Diseases and Therapy. 9(3). 641–656. 4 indexed citations
2.
Vesikari, Timo, Lars Østergaard, Johannes Beeslaar, et al.. (2019). Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. Vaccine. 37(12). 1710–1719. 28 indexed citations
3.
Taha, Muhamed‐Kheir, Paul Liberator, Ala‐Eddine Deghmane, et al.. (2017). Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 35(11). 1530–1537. 23 indexed citations
4.
Senders, Shelly, Prakash Bhuyan, Qin Jiang, et al.. (2016). Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. The Pediatric Infectious Disease Journal. 35(5). 548–554. 34 indexed citations
5.
Vesikari, Timo, Jacek Wysocki, Johannes Beeslaar, et al.. (2016). Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society. 5(2). 180–187. 30 indexed citations
7.
Vesikari, Timo, Lars Østergaard, Javier Díez‐Domingo, et al.. (2015). Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society. 5(2). 152–160. 45 indexed citations
8.
Reiner, David, Prakash Bhuyan, Joseph Eiden, et al.. (2015). Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Vaccine. 34(6). 809–813. 11 indexed citations
9.
Parks, Christopher L., Theresa Latham, Robert E. O’Neill, et al.. (2007). Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain. Virology. 367(2). 275–287. 11 indexed citations
10.
Buonagurio, Deborah A., Robert E. O’Neill, Haiping Wang, et al.. (2006). Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology. 347(2). 296–306. 24 indexed citations
11.
Buonagurio, Deborah A., Chin‐Fen Yang, Haiping Wang, et al.. (2005). Genetic stability of live, cold-adapted influenza virus components of the FluMist®/CAIV-T vaccine throughout the manufacturing process. Vaccine. 24(12). 2151–2160. 25 indexed citations
12.
Salvatore, Mirella, Robert E. O’Neill, Hongyong Zheng, et al.. (2000). Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proceedings of the National Academy of Sciences. 97(8). 4309–4314. 260 indexed citations
13.
Wolff, Thorsten, Robert E. O’Neill, & Peter Palese. (1998). NS1-Binding Protein (NS1-BP): a Novel Human Protein That Interacts with the Influenza A Virus Nonstructural NS1 Protein Is Relocalized in the Nuclei of Infected Cells. Journal of Virology. 72(9). 7170–7180. 109 indexed citations
14.
Watson, Danny F., J. Alejandro Donoso, Robert E. O’Neill, & Fred Samson. (1980). Axoplasmic transport with velocities induced by pargyline. Journal of Neuroscience Research. 5(6). 563–578. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026